C Difficile

9693 bookmarks
Newest
[Clostridioides difficile infection diagnosed by nucleic acid amplification test in a patient with Epstein-Barr Virus-related T-cell lymphoproliferative disorder] - PubMed
[Clostridioides difficile infection diagnosed by nucleic acid amplification test in a patient with Epstein-Barr Virus-related T-cell lymphoproliferative disorder] - PubMed
Steroid usage poses a risk of Clostridioides difficile infection (CDI), but high-dose corticosteroid treatment can lead to false-negative CD toxin test results. Moreover, CDI-induced nausea can complicate administration of oral antibiotics, which are typically the primary therapy for CDI. In the pre …
·pubmed.ncbi.nlm.nih.gov·
[Clostridioides difficile infection diagnosed by nucleic acid amplification test in a patient with Epstein-Barr Virus-related T-cell lymphoproliferative disorder] - PubMed
Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022 - PubMed
Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022 - PubMed
Biofilm formation and toxin production are some of the virulence factors of Clostridioides difficile (C. difficile), which causes hospital-acquired C. difficile infection (HA-CDI). This work investigated the prevalence and distribution of different strains recovered from HA-CDI patients hospitalized …
·pubmed.ncbi.nlm.nih.gov·
Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020-2022 - PubMed
Diagnosis and management of Clostridioides difficile in inflammatory bowel disease - PubMed
Diagnosis and management of Clostridioides difficile in inflammatory bowel disease - PubMed
Patients with IBD have an increased risk for Clostridioides difficile infection (CDI), which can lead to worse IBD outcomes. The diagnosis of CDI in IBD patients is complicated by higher C. difficile colonization rates and shared clinical symptoms of intestinal inflammation. Traditional risk factors …
·pubmed.ncbi.nlm.nih.gov·
Diagnosis and management of Clostridioides difficile in inflammatory bowel disease - PubMed
Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies - PubMed
Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies - PubMed
The potential role of nemonoxacin, which can be administered parenterally, for treating CDIs was evidenced through the in vitro, ex vivo, and mouse models.
·pubmed.ncbi.nlm.nih.gov·
Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies - PubMed
Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020–2022
Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020–2022
Scientific Reports - Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020–2022
·nature.com·
Virulence factors, antibiotic susceptibility and sequence type distribution of hospital-associated Clostridioides difficile isolates in Israel, 2020–2022
Diagnosis and management of Clostridioides difficile in inflammatory bowel disease - PubMed
Diagnosis and management of Clostridioides difficile in inflammatory bowel disease - PubMed
Patients with IBD have an increased risk for Clostridioides difficile infection (CDI), which can lead to worse IBD outcomes. The diagnosis of CDI in IBD patients is complicated by higher C. difficile colonization rates and shared clinical symptoms of intestinal inflammation. Traditional risk factors …
·pubmed.ncbi.nlm.nih.gov·
Diagnosis and management of Clostridioides difficile in inflammatory bowel disease - PubMed
Human microbiome: Impact of newly approved treatments on C. difficile infection - PubMed
Human microbiome: Impact of newly approved treatments on C. difficile infection - PubMed
Live microbiome therapy is a promising solution for patients with recurrent CDI. Future studies should provide further evidence within yet-to-be-evaluated populations not included in registry studies. This along with real-world evidence will inform future use and clinical guideline placement.
·pubmed.ncbi.nlm.nih.gov·
Human microbiome: Impact of newly approved treatments on C. difficile infection - PubMed
Infection Prevention Leadership Search: Insights and Advice From Tamara Behm, MSN, RN, CIC, FAPIC, CER, CQIA, CCSVP, CAIP
Infection Prevention Leadership Search: Insights and Advice From Tamara Behm, MSN, RN, CIC, FAPIC, CER, CQIA, CCSVP, CAIP
Discover Tamara Behm's journey in seeking an IP leadership role, her passion for patient safety, and advice for job-seeking professionals in infection prevention, in this discussion with ICT’s IPLifeline.
·infectioncontroltoday.com·
Infection Prevention Leadership Search: Insights and Advice From Tamara Behm, MSN, RN, CIC, FAPIC, CER, CQIA, CCSVP, CAIP
Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies - PubMed
Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies - PubMed
The potential role of nemonoxacin, which can be administered parenterally, for treating CDIs was evidenced through the in vitro, ex vivo, and mouse models.
·pubmed.ncbi.nlm.nih.gov·
Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies - PubMed
Preferences for a Clostridioides difficile vaccine among adults in the United States - PubMed
Preferences for a Clostridioides difficile vaccine among adults in the United States - PubMed
OOP cost, improvements in vaccine effectiveness, and reduction in CDI severity were highly influential to vaccine selection. Most adults aged ≥50 years were receptive to a C.diff vaccine, especially with little-to-no OOP cost, suggesting that mandating insurance coverage of vaccination with no copay …
·pubmed.ncbi.nlm.nih.gov·
Preferences for a Clostridioides difficile vaccine among adults in the United States - PubMed
Bile acids impact the microbiota, host, and C. difficile dynamics providing insight into mechanisms of efficacy of FMTs and microbiota-focused therapeutics - PubMed
Bile acids impact the microbiota, host, and C. difficile dynamics providing insight into mechanisms of efficacy of FMTs and microbiota-focused therapeutics - PubMed
Clostridioides difficile is a major nosocomial pathogen, causing significant morbidity and mortality worldwide. Antibiotic usage, a major risk factor for Clostridioides difficile infection (CDI), disrupts the gut microbiota, allowing C. difficile to proliferate and cause infecti …
·pubmed.ncbi.nlm.nih.gov·
Bile acids impact the microbiota, host, and C. difficile dynamics providing insight into mechanisms of efficacy of FMTs and microbiota-focused therapeutics - PubMed
Development and evaluation of a rapid visual loop-mediated isothermal amplification assay for the tcdA gene in Clostridioides difficile detection - PubMed
Development and evaluation of a rapid visual loop-mediated isothermal amplification assay for the tcdA gene in Clostridioides difficile detection - PubMed
LAMP method is an effective technique for the rapid and visual detection of the tcdA gene of C. difficile, and shows potential advantages over PCR in terms of speed, simplicity, and sensitivity. The tcdA-LAMP assay is particularly suitable for medical diagnostic environments wit …
·pubmed.ncbi.nlm.nih.gov·
Development and evaluation of a rapid visual loop-mediated isothermal amplification assay for the tcdA gene in Clostridioides difficile detection - PubMed
Preferences for a Clostridioides difficile vaccine among adults in the United States - PubMed
Preferences for a Clostridioides difficile vaccine among adults in the United States - PubMed
OOP cost, improvements in vaccine effectiveness, and reduction in CDI severity were highly influential to vaccine selection. Most adults aged ≥50 years were receptive to a C.diff vaccine, especially with little-to-no OOP cost, suggesting that mandating insurance coverage of vaccination with no copay …
·pubmed.ncbi.nlm.nih.gov·
Preferences for a Clostridioides difficile vaccine among adults in the United States - PubMed
How to develop a Controlled Human Infection Model for Clostridioides difficile - PubMed
How to develop a Controlled Human Infection Model for Clostridioides difficile - PubMed
Should these challenges be tackled, a C. difficile CHIM not only provides a way forward for the testing of novel products but also offers a framework for better understanding of the pathophysiology, pathogenesis and immunology of C. difficile colonisation and infection.
·pubmed.ncbi.nlm.nih.gov·
How to develop a Controlled Human Infection Model for Clostridioides difficile - PubMed
Interplay between Bile Acids and Intestinal Microbiota: Regulatory Mechanisms and Therapeutic Potential for Infections - PubMed
Interplay between Bile Acids and Intestinal Microbiota: Regulatory Mechanisms and Therapeutic Potential for Infections - PubMed
Bile acids (BAs) play a crucial role in the human body's defense against infections caused by bacteria, fungi, and viruses. BAs counteract infections not only through interactions with intestinal bacteria exhibiting bile salt hydrolase (BSH) activity but they also directly combat infections. Buildin …
·pubmed.ncbi.nlm.nih.gov·
Interplay between Bile Acids and Intestinal Microbiota: Regulatory Mechanisms and Therapeutic Potential for Infections - PubMed
Clinical sequelae of gut microbiome development and disruption in hospitalized preterm infants - PubMed
Clinical sequelae of gut microbiome development and disruption in hospitalized preterm infants - PubMed
Aberrant preterm infant gut microbiota assembly predisposes to early-life disorders and persistent health problems. Here, we characterize gut microbiome dynamics over the first 3 months of life in 236 preterm infants hospitalized in three neonatal intensive care units using shotgun metagenomics of 2 …
·pubmed.ncbi.nlm.nih.gov·
Clinical sequelae of gut microbiome development and disruption in hospitalized preterm infants - PubMed
Clostridioides difficile Infection: Use of Inflammatory Biomarkers and Hemogram-Derived Ratios to Predict Mortality Risk in Hospitalized Patients - PubMed
Clostridioides difficile Infection: Use of Inflammatory Biomarkers and Hemogram-Derived Ratios to Predict Mortality Risk in Hospitalized Patients - PubMed
Neutrophils, dNLR, NLR, SII, and PNR are valuable biomarkers for predicting mortality in CDI patients. Understanding these predictors can improve risk stratification and clinical outcomes for CDI patients.
·pubmed.ncbi.nlm.nih.gov·
Clostridioides difficile Infection: Use of Inflammatory Biomarkers and Hemogram-Derived Ratios to Predict Mortality Risk in Hospitalized Patients - PubMed
Prevalence of Enteric Pathogens and Antibiotic Resistance: Results of a Six-Year Active Surveillance Study on Patients Admitted to a Teaching Hospital - PubMed
Prevalence of Enteric Pathogens and Antibiotic Resistance: Results of a Six-Year Active Surveillance Study on Patients Admitted to a Teaching Hospital - PubMed
Timely notification of gastroenteric infections is crucial in identifying potential outbreak sources and ensuring strict adherence to food safety and hygiene practices, so as to protect the most vulnerable populations. The present study offers insights into the epidemiological characteristics and th …
·pubmed.ncbi.nlm.nih.gov·
Prevalence of Enteric Pathogens and Antibiotic Resistance: Results of a Six-Year Active Surveillance Study on Patients Admitted to a Teaching Hospital - PubMed
A New Convenient Method to Assess Antibiotic Resistance and Antimicrobial Efficacy against Pathogenic Clostridioides difficile Biofilms - PubMed
A New Convenient Method to Assess Antibiotic Resistance and Antimicrobial Efficacy against Pathogenic Clostridioides difficile Biofilms - PubMed
Clostridioides difficile is a widely distributed anaerobic pathogen. C. difficile infection is a serious problem in healthcare. Its biofilms have been found to exhibit biocorrosivity, albeit very little, but sufficient for it to correlate with biofilm growth/health. This work demonstra …
·pubmed.ncbi.nlm.nih.gov·
A New Convenient Method to Assess Antibiotic Resistance and Antimicrobial Efficacy against Pathogenic Clostridioides difficile Biofilms - PubMed
Diverse Sources and Latent Reservoirs of Community-Associated Clostridioides difficile Infection - PubMed
Diverse Sources and Latent Reservoirs of Community-Associated Clostridioides difficile Infection - PubMed
Clostridioides difficile (C. difficile) is a spore-forming, toxin-producing, anaerobic bacterium infecting the human gastrointestinal tract, causing diarrhea and life-threatening colitis. C. difficile epidemiology continues to evolve, and it is recognized as a major community-associated pathogen in …
·pubmed.ncbi.nlm.nih.gov·
Diverse Sources and Latent Reservoirs of Community-Associated Clostridioides difficile Infection - PubMed
Validation of Lyophilized Human Fecal Microbiota for the Treatment of Clostridioides difficile Infection: A Pilot Study with Pharmacoeconomic Analysis of a Middle-Income Country-Promicrobioma Project - PubMed
Validation of Lyophilized Human Fecal Microbiota for the Treatment of Clostridioides difficile Infection: A Pilot Study with Pharmacoeconomic Analysis of a Middle-Income Country-Promicrobioma Project - PubMed
The lyophilized human fecal microbiota for transplant is safe and can be an important step for a new product with low cost, even with genomic sequencing. Fecal microbiota transplantation emerges as a more cost-effective alternative compared to antimicrobials in the retreatment of CDI.
·pubmed.ncbi.nlm.nih.gov·
Validation of Lyophilized Human Fecal Microbiota for the Treatment of Clostridioides difficile Infection: A Pilot Study with Pharmacoeconomic Analysis of a Middle-Income Country-Promicrobioma Project - PubMed
Clostridioides difficile and Gut Microbiota: From Colonization to Infection and Treatment - PubMed
Clostridioides difficile and Gut Microbiota: From Colonization to Infection and Treatment - PubMed
Clostridioides difficile is the main causative agent of antibiotic-associated diarrhea (AAD) in hospitals in the developed world. Both infected patients and asymptomatic colonized individuals represent important transmission sources of C. difficile. C. difficile infection (CDI) …
·pubmed.ncbi.nlm.nih.gov·
Clostridioides difficile and Gut Microbiota: From Colonization to Infection and Treatment - PubMed